Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Identifieur interne : 002D97 ( Ncbi/Merge ); précédent : 002D96; suivant : 002D98Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Auteurs : Ruben Mesa [États-Unis] ; Srdan Verstovsek [États-Unis] ; Jean-Jacques Kiladjian [France] ; Martin Griesshammer [Allemagne] ; Tamas Masszi [Hongrie] ; Simon Durrant [Australie] ; Francesco Passamonti [Italie] ; Claire N. Harrison [Royaume-Uni] ; Fabrizio Pane [Italie] ; Pierre Zachee [Belgique] ; Huiling Zhen [États-Unis] ; Mark M. Jones [États-Unis] ; Shreekant Parasuraman [États-Unis] ; Jingjin Li [États-Unis] ; Isabelle Côté [États-Unis] ; Dany Habr [États-Unis] ; Alessandro M. Vannucchi [Italie]Source :
- European journal of haematology [ 1600-0609 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Femelle, Humains, Inhibiteurs de protéines kinases (administration et posologie), Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Mesures des résultats rapportés par les patients, Mâle, Norme de soins, Polyglobulie primitive essentielle (), Polyglobulie primitive essentielle (diagnostic), Polyglobulie primitive essentielle (épidémiologie), Pyrazoles (administration et posologie), Pyrazoles (effets indésirables), Pyrazoles (usage thérapeutique), Qualité de vie, Résultat thérapeutique, Sujet âgé.
- MESH :
- administration et posologie : Inhibiteurs de protéines kinases, Pyrazoles.
- diagnostic : Polyglobulie primitive essentielle.
- effets indésirables : Inhibiteurs de protéines kinases, Pyrazoles.
- usage thérapeutique : Inhibiteurs de protéines kinases, Pyrazoles.
- épidémiologie : Polyglobulie primitive essentielle.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mesures des résultats rapportés par les patients, Mâle, Norme de soins, Polyglobulie primitive essentielle, Qualité de vie, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Adult, Aged, Female, Humans, Male, Middle Aged, Patient Reported Outcome Measures, Polycythemia Vera (diagnosis), Polycythemia Vera (epidemiology), Polycythemia Vera (therapy), Protein Kinase Inhibitors (administration & dosage), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyrazoles (administration & dosage), Pyrazoles (adverse effects), Pyrazoles (therapeutic use), Quality of Life, Standard of Care, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Protein Kinase Inhibitors, Pyrazoles.
- chemical , adverse effects : Protein Kinase Inhibitors, Pyrazoles.
- diagnosis : Polycythemia Vera.
- epidemiology : Polycythemia Vera.
- chemical , therapeutic use : Protein Kinase Inhibitors, Pyrazoles.
- therapy : Polycythemia Vera.
- Adult, Aged, Female, Humans, Male, Middle Aged, Patient Reported Outcome Measures, Quality of Life, Standard of Care, Treatment Outcome.
Abstract
Polycythemia vera (PV)-related symptoms may not be adequately controlled with conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of ruxolitinib compared with standard therapy on quality of life (QoL) and symptoms in patients with PV who were hydroxyurea resistant/intolerant.
DOI: 10.1111/ejh.12707
PubMed: 26608702
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001B58
- to stream PubMed, to step Curation: 001B34
- to stream PubMed, to step Checkpoint: 001B34
Links to Exploration step
pubmed:26608702Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.</title><author><name sortKey="Mesa, Ruben" sort="Mesa, Ruben" uniqKey="Mesa R" first="Ruben" last="Mesa">Ruben Mesa</name><affiliation wicri:level="2"><nlm:affiliation>Mayo Clinic Cancer Center, Scottsdale, AZ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic Cancer Center, Scottsdale, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Verstovsek, Srdan" sort="Verstovsek, Srdan" uniqKey="Verstovsek S" first="Srdan" last="Verstovsek">Srdan Verstovsek</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kiladjian, Jean Jacques" sort="Kiladjian, Jean Jacques" uniqKey="Kiladjian J" first="Jean-Jacques" last="Kiladjian">Jean-Jacques Kiladjian</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint-Louis et Université Paris Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint-Louis et Université Paris Diderot, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Griesshammer, Martin" sort="Griesshammer, Martin" uniqKey="Griesshammer M" first="Martin" last="Griesshammer">Martin Griesshammer</name><affiliation wicri:level="1"><nlm:affiliation>Johannes Wesling Clinic, Minden, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Johannes Wesling Clinic, Minden</wicri:regionArea><wicri:noRegion>Minden</wicri:noRegion><wicri:noRegion>Minden</wicri:noRegion><wicri:noRegion>Minden</wicri:noRegion></affiliation></author><author><name sortKey="Masszi, Tamas" sort="Masszi, Tamas" uniqKey="Masszi T" first="Tamas" last="Masszi">Tamas Masszi</name><affiliation wicri:level="3"><nlm:affiliation>St. István and St. László Hospital, Budapest, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>St. István and St. László Hospital, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation wicri:level="1"><nlm:affiliation>Royal Brisbane & Women's Hospital, Brisbane, Qld, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Brisbane & Women's Hospital, Brisbane, Qld</wicri:regionArea><wicri:noRegion>Qld</wicri:noRegion></affiliation></author><author><name sortKey="Passamonti, Francesco" sort="Passamonti, Francesco" uniqKey="Passamonti F" first="Francesco" last="Passamonti">Francesco Passamonti</name><affiliation wicri:level="1"><nlm:affiliation>Ospedale di Circolo e Fondazione Macchi, Varese, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale di Circolo e Fondazione Macchi, Varese</wicri:regionArea><wicri:noRegion>Varese</wicri:noRegion></affiliation></author><author><name sortKey="Harrison, Claire N" sort="Harrison, Claire N" uniqKey="Harrison C" first="Claire N" last="Harrison">Claire N. Harrison</name><affiliation wicri:level="3"><nlm:affiliation>Guy's and St. Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Guy's and St. Thomas' NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pane, Fabrizio" sort="Pane, Fabrizio" uniqKey="Pane F" first="Fabrizio" last="Pane">Fabrizio Pane</name><affiliation wicri:level="1"><nlm:affiliation>University of Naples Federico II, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>University of Naples Federico II, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Zachee, Pierre" sort="Zachee, Pierre" uniqKey="Zachee P" first="Pierre" last="Zachee">Pierre Zachee</name><affiliation wicri:level="1"><nlm:affiliation>ZNA Stuivenberg, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>ZNA Stuivenberg, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Zhen, Huiling" sort="Zhen, Huiling" uniqKey="Zhen H" first="Huiling" last="Zhen">Huiling Zhen</name><affiliation wicri:level="2"><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Incyte Corporation, Wilmington, DE</wicri:regionArea><placeName><region type="state">Delaware</region></placeName></affiliation></author><author><name sortKey="Jones, Mark M" sort="Jones, Mark M" uniqKey="Jones M" first="Mark M" last="Jones">Mark M. Jones</name><affiliation wicri:level="2"><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Incyte Corporation, Wilmington, DE</wicri:regionArea><placeName><region type="state">Delaware</region></placeName></affiliation></author><author><name sortKey="Parasuraman, Shreekant" sort="Parasuraman, Shreekant" uniqKey="Parasuraman S" first="Shreekant" last="Parasuraman">Shreekant Parasuraman</name><affiliation wicri:level="2"><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Incyte Corporation, Wilmington, DE</wicri:regionArea><placeName><region type="state">Delaware</region></placeName></affiliation></author><author><name sortKey="Li, Jingjin" sort="Li, Jingjin" uniqKey="Li J" first="Jingjin" last="Li">Jingjin Li</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Cote, Isabelle" sort="Cote, Isabelle" uniqKey="Cote I" first="Isabelle" last="Côté">Isabelle Côté</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Habr, Dany" sort="Habr, Dany" uniqKey="Habr D" first="Dany" last="Habr">Dany Habr</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Vannucchi, Alessandro M" sort="Vannucchi, Alessandro M" uniqKey="Vannucchi A" first="Alessandro M" last="Vannucchi">Alessandro M. Vannucchi</name><affiliation wicri:level="1"><nlm:affiliation>University of Florence, Florence, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>University of Florence, Florence</wicri:regionArea><wicri:noRegion>Florence</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26608702</idno><idno type="pmid">26608702</idno><idno type="doi">10.1111/ejh.12707</idno><idno type="wicri:Area/PubMed/Corpus">001B58</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B58</idno><idno type="wicri:Area/PubMed/Curation">001B34</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B34</idno><idno type="wicri:Area/PubMed/Checkpoint">001B34</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B34</idno><idno type="wicri:Area/Ncbi/Merge">002D97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.</title><author><name sortKey="Mesa, Ruben" sort="Mesa, Ruben" uniqKey="Mesa R" first="Ruben" last="Mesa">Ruben Mesa</name><affiliation wicri:level="2"><nlm:affiliation>Mayo Clinic Cancer Center, Scottsdale, AZ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic Cancer Center, Scottsdale, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Verstovsek, Srdan" sort="Verstovsek, Srdan" uniqKey="Verstovsek S" first="Srdan" last="Verstovsek">Srdan Verstovsek</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kiladjian, Jean Jacques" sort="Kiladjian, Jean Jacques" uniqKey="Kiladjian J" first="Jean-Jacques" last="Kiladjian">Jean-Jacques Kiladjian</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint-Louis et Université Paris Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint-Louis et Université Paris Diderot, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Griesshammer, Martin" sort="Griesshammer, Martin" uniqKey="Griesshammer M" first="Martin" last="Griesshammer">Martin Griesshammer</name><affiliation wicri:level="1"><nlm:affiliation>Johannes Wesling Clinic, Minden, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Johannes Wesling Clinic, Minden</wicri:regionArea><wicri:noRegion>Minden</wicri:noRegion><wicri:noRegion>Minden</wicri:noRegion><wicri:noRegion>Minden</wicri:noRegion></affiliation></author><author><name sortKey="Masszi, Tamas" sort="Masszi, Tamas" uniqKey="Masszi T" first="Tamas" last="Masszi">Tamas Masszi</name><affiliation wicri:level="3"><nlm:affiliation>St. István and St. László Hospital, Budapest, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>St. István and St. László Hospital, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation wicri:level="1"><nlm:affiliation>Royal Brisbane & Women's Hospital, Brisbane, Qld, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Brisbane & Women's Hospital, Brisbane, Qld</wicri:regionArea><wicri:noRegion>Qld</wicri:noRegion></affiliation></author><author><name sortKey="Passamonti, Francesco" sort="Passamonti, Francesco" uniqKey="Passamonti F" first="Francesco" last="Passamonti">Francesco Passamonti</name><affiliation wicri:level="1"><nlm:affiliation>Ospedale di Circolo e Fondazione Macchi, Varese, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale di Circolo e Fondazione Macchi, Varese</wicri:regionArea><wicri:noRegion>Varese</wicri:noRegion></affiliation></author><author><name sortKey="Harrison, Claire N" sort="Harrison, Claire N" uniqKey="Harrison C" first="Claire N" last="Harrison">Claire N. Harrison</name><affiliation wicri:level="3"><nlm:affiliation>Guy's and St. Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Guy's and St. Thomas' NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pane, Fabrizio" sort="Pane, Fabrizio" uniqKey="Pane F" first="Fabrizio" last="Pane">Fabrizio Pane</name><affiliation wicri:level="1"><nlm:affiliation>University of Naples Federico II, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>University of Naples Federico II, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Zachee, Pierre" sort="Zachee, Pierre" uniqKey="Zachee P" first="Pierre" last="Zachee">Pierre Zachee</name><affiliation wicri:level="1"><nlm:affiliation>ZNA Stuivenberg, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>ZNA Stuivenberg, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Zhen, Huiling" sort="Zhen, Huiling" uniqKey="Zhen H" first="Huiling" last="Zhen">Huiling Zhen</name><affiliation wicri:level="2"><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Incyte Corporation, Wilmington, DE</wicri:regionArea><placeName><region type="state">Delaware</region></placeName></affiliation></author><author><name sortKey="Jones, Mark M" sort="Jones, Mark M" uniqKey="Jones M" first="Mark M" last="Jones">Mark M. Jones</name><affiliation wicri:level="2"><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Incyte Corporation, Wilmington, DE</wicri:regionArea><placeName><region type="state">Delaware</region></placeName></affiliation></author><author><name sortKey="Parasuraman, Shreekant" sort="Parasuraman, Shreekant" uniqKey="Parasuraman S" first="Shreekant" last="Parasuraman">Shreekant Parasuraman</name><affiliation wicri:level="2"><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Incyte Corporation, Wilmington, DE</wicri:regionArea><placeName><region type="state">Delaware</region></placeName></affiliation></author><author><name sortKey="Li, Jingjin" sort="Li, Jingjin" uniqKey="Li J" first="Jingjin" last="Li">Jingjin Li</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Cote, Isabelle" sort="Cote, Isabelle" uniqKey="Cote I" first="Isabelle" last="Côté">Isabelle Côté</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Habr, Dany" sort="Habr, Dany" uniqKey="Habr D" first="Dany" last="Habr">Dany Habr</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Vannucchi, Alessandro M" sort="Vannucchi, Alessandro M" uniqKey="Vannucchi A" first="Alessandro M" last="Vannucchi">Alessandro M. Vannucchi</name><affiliation wicri:level="1"><nlm:affiliation>University of Florence, Florence, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>University of Florence, Florence</wicri:regionArea><wicri:noRegion>Florence</wicri:noRegion></affiliation></author></analytic><series><title level="j">European journal of haematology</title><idno type="eISSN">1600-0609</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Reported Outcome Measures</term><term>Polycythemia Vera (diagnosis)</term><term>Polycythemia Vera (epidemiology)</term><term>Polycythemia Vera (therapy)</term><term>Protein Kinase Inhibitors (administration & dosage)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrazoles (administration & dosage)</term><term>Pyrazoles (adverse effects)</term><term>Pyrazoles (therapeutic use)</term><term>Quality of Life</term><term>Standard of Care</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (administration et posologie)</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Mesures des résultats rapportés par les patients</term><term>Mâle</term><term>Norme de soins</term><term>Polyglobulie primitive essentielle ()</term><term>Polyglobulie primitive essentielle (diagnostic)</term><term>Polyglobulie primitive essentielle (épidémiologie)</term><term>Pyrazoles (administration et posologie)</term><term>Pyrazoles (effets indésirables)</term><term>Pyrazoles (usage thérapeutique)</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Polycythemia Vera</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Polyglobulie primitive essentielle</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Polycythemia Vera</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Polycythemia Vera</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Polyglobulie primitive essentielle</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Reported Outcome Measures</term><term>Quality of Life</term><term>Standard of Care</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mesures des résultats rapportés par les patients</term><term>Mâle</term><term>Norme de soins</term><term>Polyglobulie primitive essentielle</term><term>Qualité de vie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Polycythemia vera (PV)-related symptoms may not be adequately controlled with conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of ruxolitinib compared with standard therapy on quality of life (QoL) and symptoms in patients with PV who were hydroxyurea resistant/intolerant.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26608702</PMID><DateCreated><Year>2016</Year><Month>07</Month><Day>06</Day></DateCreated><DateCompleted><Year>2017</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0609</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of haematology</Title><ISOAbbreviation>Eur. J. Haematol.</ISOAbbreviation></Journal><ArticleTitle>Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.</ArticleTitle><Pagination><MedlinePgn>192-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ejh.12707</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Polycythemia vera (PV)-related symptoms may not be adequately controlled with conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of ruxolitinib compared with standard therapy on quality of life (QoL) and symptoms in patients with PV who were hydroxyurea resistant/intolerant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the previously reported primary analysis, ruxolitinib achieved the primary composite endpoint of hematocrit control and ≥35% reduction in spleen volume at Week 32. The current analysis evaluated patient-reported outcomes using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF), the Pruritus Symptom Impact Scale (PSIS), and the Patient Global Impression of Change (PGIC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with standard therapy, ruxolitinib was associated with greater improvements in global health status/QoL, functional subscales, and individual symptom scores of the EORTC QLQ-C30. At Week 32, more patients in the ruxolitinib arm (44%) achieved a ≥10-point improvement in global health status/QoL vs. standard therapy (9%). Improvements in MPN-SAF symptom scores were consistent with improvements in EORTC QLQ-C30, PSIS, and PGIC scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ruxolitinib provides clinically relevant improvements in QoL and ameliorates symptom burden in patients with PV who are hydroxyurea resistant/intolerant.</AbstractText><CopyrightInformation>© 2016 The Authors. European Journal of Haematology Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mesa</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mayo Clinic Cancer Center, Scottsdale, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verstovsek</LastName><ForeName>Srdan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiladjian</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Hôpital Saint-Louis et Université Paris Diderot, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griesshammer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Johannes Wesling Clinic, Minden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masszi</LastName><ForeName>Tamas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>St. István and St. László Hospital, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durrant</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Royal Brisbane & Women's Hospital, Brisbane, Qld, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passamonti</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ospedale di Circolo e Fondazione Macchi, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Claire N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Guy's and St. Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pane</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachee</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ZNA Stuivenberg, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhen</LastName><ForeName>Huiling</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Incyte Corporation, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Incyte Corporation, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parasuraman</LastName><ForeName>Shreekant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Incyte Corporation, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingjin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Côté</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habr</LastName><ForeName>Dany</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vannucchi</LastName><ForeName>Alessandro M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Haematol</MedlineTA><NlmUniqueID>8703985</NlmUniqueID><ISSNLinking>0902-4441</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540383">INCB018424</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011087" MajorTopicYN="N">Polycythemia Vera</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059039" MajorTopicYN="Y">Standard of Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">polycythemia vera</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">signs and symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26608702</ArticleId><ArticleId IdType="doi">10.1111/ejh.12707</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>France</li><li>Hongrie</li><li>Italie</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Arizona</li><li>Delaware</li><li>Grand Londres</li><li>Hongrie centrale</li><li>New Jersey</li><li>Texas</li><li>Île-de-France</li></region><settlement><li>Budapest</li><li>Londres</li><li>Paris</li></settlement></list><tree><country name="États-Unis"><region name="Arizona"><name sortKey="Mesa, Ruben" sort="Mesa, Ruben" uniqKey="Mesa R" first="Ruben" last="Mesa">Ruben Mesa</name></region><name sortKey="Cote, Isabelle" sort="Cote, Isabelle" uniqKey="Cote I" first="Isabelle" last="Côté">Isabelle Côté</name><name sortKey="Habr, Dany" sort="Habr, Dany" uniqKey="Habr D" first="Dany" last="Habr">Dany Habr</name><name sortKey="Jones, Mark M" sort="Jones, Mark M" uniqKey="Jones M" first="Mark M" last="Jones">Mark M. Jones</name><name sortKey="Li, Jingjin" sort="Li, Jingjin" uniqKey="Li J" first="Jingjin" last="Li">Jingjin Li</name><name sortKey="Parasuraman, Shreekant" sort="Parasuraman, Shreekant" uniqKey="Parasuraman S" first="Shreekant" last="Parasuraman">Shreekant Parasuraman</name><name sortKey="Verstovsek, Srdan" sort="Verstovsek, Srdan" uniqKey="Verstovsek S" first="Srdan" last="Verstovsek">Srdan Verstovsek</name><name sortKey="Zhen, Huiling" sort="Zhen, Huiling" uniqKey="Zhen H" first="Huiling" last="Zhen">Huiling Zhen</name></country><country name="France"><region name="Île-de-France"><name sortKey="Kiladjian, Jean Jacques" sort="Kiladjian, Jean Jacques" uniqKey="Kiladjian J" first="Jean-Jacques" last="Kiladjian">Jean-Jacques Kiladjian</name></region></country><country name="Allemagne"><noRegion><name sortKey="Griesshammer, Martin" sort="Griesshammer, Martin" uniqKey="Griesshammer M" first="Martin" last="Griesshammer">Martin Griesshammer</name></noRegion></country><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Masszi, Tamas" sort="Masszi, Tamas" uniqKey="Masszi T" first="Tamas" last="Masszi">Tamas Masszi</name></region></country><country name="Australie"><noRegion><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Passamonti, Francesco" sort="Passamonti, Francesco" uniqKey="Passamonti F" first="Francesco" last="Passamonti">Francesco Passamonti</name></noRegion><name sortKey="Pane, Fabrizio" sort="Pane, Fabrizio" uniqKey="Pane F" first="Fabrizio" last="Pane">Fabrizio Pane</name><name sortKey="Vannucchi, Alessandro M" sort="Vannucchi, Alessandro M" uniqKey="Vannucchi A" first="Alessandro M" last="Vannucchi">Alessandro M. Vannucchi</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Harrison, Claire N" sort="Harrison, Claire N" uniqKey="Harrison C" first="Claire N" last="Harrison">Claire N. Harrison</name></region></country><country name="Belgique"><noRegion><name sortKey="Zachee, Pierre" sort="Zachee, Pierre" uniqKey="Zachee P" first="Pierre" last="Zachee">Pierre Zachee</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002D97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:26608702
|texte= Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:26608702" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |